Routine

Statin intolerance & lipid-lowering escalation

Managing statin side effects · Cardiac
Physician-written · Verified by three sets of doctors · Reviewed November 2026

Bedside summary

True statin intolerance is uncommon; most muscle symptoms are not caused by the statin on rechallenge. A structured approach distinguishes genuine intolerance from nocebo effect and uses alternative agents to still reach LDL-C goals.

Red flags

  • CK >10x upper limit of normal
  • Dark urine or marked weakness (rhabdomyolysis)
  • Muscle symptoms with acute kidney injury
  • Jaundice or marked transaminase rise
  • Symptoms persisting after full statin washout (seek alternative cause)

Assessment

Differential diagnosis

  • Nocebo/drug-aware muscle symptoms
  • Vitamin D deficiency myalgia
  • Hypothyroid myopathy
  • Polymyalgia rheumatica
  • Drug-interaction myopathy
  • True statin-associated myopathy/rhabdomyolysis

Investigations

  • Creatine kinase during symptoms
  • TSH to exclude hypothyroidism
  • Vitamin D level
  • Renal and liver function
  • Review of interacting drugs (fibrates, macrolides, azoles)
  • Repeat lipid profile to document control

Management

  • Characterise symptoms, timing and relation to statin exposure
  • Check CK and exclude secondary myopathy causes and drug interactions
  • Stop the statin temporarily to assess symptom resolution if CK markedly raised
  • Correct vitamin D and thyroid deficiency if present
  • Rechallenge with the same or a different statin at a lower dose
  • Trial intermittent dosing (e.g. alternate-day or twice-weekly rosuvastatin)
  • Add ezetimibe to a low statin dose to reach target
  • Use bempedoic acid in genuine intolerance
  • Add a PCSK9 inhibitor or inclisiran if still above goal
  • Stop the statin and seek urgent review if CK >10x ULN or rhabdomyolysis signs
  • Document true intolerance only after ≥2 statins failed including low-dose rechallenge
  • Reassess lipid goal attainment and cardiovascular risk

Drugs & doses

Rosuvastatin 5 mg PO twice weekly (intermittent regimen)
Atorvastatin 10 mg PO alternate days (low-dose trial)
Ezetimibe 10 mg PO OD
Bempedoic acid 180 mg PO OD
Alirocumab 75 mg SC every 2 weeks (or evolocumab 140 mg SC every 2 weeks)
Inclisiran 284 mg SC at 0, 3 months then 6-monthly

Disposition

GP or lipid clinic management; refer for PCSK9 inhibitor funding assessment or if genuinely multi-statin intolerant with high risk.

Complications & pitfalls

  • Rhabdomyolysis (rare)
  • Under-treated cardiovascular risk from statin avoidance
  • Hepatotoxicity (very rare)
  • Missed alternative myopathy diagnosis
  • New-onset diabetes (small absolute risk)

Exam pearls

  • Most patients tolerate a statin on blinded rechallenge — nocebo effect is dominant
  • Bempedoic acid is activated only in liver, sparing muscle
  • Never abandon LDL lowering — use non-statin agents to the same target
  • Hydrophilic statins (rosuvastatin, pravastatin) are often better tolerated
  • Correct vitamin D before declaring intolerance

Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.